Literature DB >> 14750075

Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.

Stephen C Jones1, Thea M Friedman, George F Murphy, Robert Korngold.   

Abstract

CXB-2/By (CXB-2) recombinant inbred mice express a subset of the minor histocompatibility antigen (miHA) repertoire expressed by C.B10-H2(b)/LiMcdJ (BALB.B) mice. On lethal irradiation and the transplantation of H2(b)-matched C57BL/6 (B6) T cell-depleted bone marrow cells, along with naive unfractionated T cells, both strains succumb to acute graft-versus-host disease (GVHD). Although alloreactive B6 CD4(+) T cells are a necessary source of T-cell help for the B6 CD8(+) component of the GVHD response in both recipient strains, they are capable of mediating severe GVHD by themselves only in BALB.B mice. Previous CD4(+) T-cell receptor repertoire analysis demonstrated overlapping oligoclonal Vbeta use between the CD4(+) B6 anti-BALB.B and B6 anti-CXB-2 responses, with indications of additional BALB.B unique T-cell responses (Vbeta2 and Vbeta11). We report here that the more severe B6 anti-BALB.B response is not due to a quantitative difference in the responding cells, because the frequency of alloreactive donor CD4(+) T cells over time was equivalent in the spleens of BALB.B versus CXB-2 recipients. The responses were also similar in the number of infiltrating B6 CD4(+) T cells in the lingual epithelium of the 2 recipients. In contrast, a significantly greater degree of infiltration and injury of BALB.B intestinal epithelium correlated with the increased level of clinical GVHD severity. Of most significance, despite the involvement of at least 11 Vbeta-associated CD4(+) T-cell families in the overall B6 anti-BALB.B response, the development of severe GVHD correlated with the presence of Vbeta2- and Vbeta11-positive donor T cells. Transplantation of donor CD4(+) T cells from Vbeta-associated families that were shared between the B6 anti-BALB.B and anti-CXB-2 responses resulted in minimal GVHD potential. These data suggest that severe GVHD across miHA barriers depends on the involvement of a restricted number of potent T-cell specificities and implies that there are only a limited number of corresponding responsible miHAs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14750075     DOI: 10.1016/j.bbmt.2003.10.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  13 in total

1.  Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model.

Authors:  Barry J Kappel; Javier Pinilla-Ibarz; Adam A Kochman; Jeffrey M Eng; Vanessa M Hubbard; Ingrid Leiner; Eric G Pamer; Glen Heller; Marcel R M van den Brink; David A Scheinberg
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

Review 2.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

3.  Inter-strain tissue-infiltrating T cell responses to minor histocompatibility antigens involved in graft-versus-host disease as determined by Vbeta spectratype analysis.

Authors:  Jenny Zilberberg; Danielle McElhaugh; Loise N Gichuru; Robert Korngold; Thea M Friedman
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

Review 4.  Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.

Authors:  Jenny Zilberberg; Rena Feinman; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

5.  Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.

Authors:  Sudipto Ganguly; Duncan B Ross; Angela Panoskaltsis-Mortari; Christopher G Kanakry; Bruce R Blazar; Robert B Levy; Leo Luznik
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

6.  T-cell receptor V(alpha) usage by effector CD4+Vbeta11+ T cells mediating graft-versus-host disease directed to minor histocompatibility antigens.

Authors:  Christine G DiRienzo; George F Murphy; Thea M Friedman; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2007-03       Impact factor: 5.742

7.  T-cell receptor Valpha spectratype analysis of a CD4-mediated T-cell response against minor histocompatibility antigens involved in severe graft-versus-host disease.

Authors:  Christine G DiRienzo; George F Murphy; Stephen C Jones; Robert Korngold; Thea M Friedman
Journal:  Biol Blood Marrow Transplant       Date:  2006-08       Impact factor: 5.742

8.  Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model.

Authors:  Stacey L Fanning; Jenny Zilberberg; Johann Stein; Kristin Vazzana; Stephanie A Berger; Robert Korngold; Thea M Friedman
Journal:  J Immunol       Date:  2012-11-30       Impact factor: 5.422

Review 9.  Target cells in graft-versus-host disease: implications for cancer therapy.

Authors:  George F Murphy
Journal:  Clin Rev Allergy Immunol       Date:  2007-08-14       Impact factor: 8.667

10.  Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation.

Authors:  Thea M Friedman; Kira Goldgirsh; Stephanie A Berger; Jenny Zilberberg; Joanne Filicko-O'Hara; Neal Flomenberg; Michele Donato; Scott D Rowley; Robert Korngold
Journal:  Blood       Date:  2008-06-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.